Dina Robaa

Dina Robaa is a researcher in the Department of Medicinal Chemistry at the Institute of Pharmacy, Faculty of Natural Sciences I - Biosciences, Martin Luther University Halle-Wittenberg. Her research focuses on structure-based design and optimization of epigenetic modulators and PROTACs, with a strong emphasis on targeting histone deacetylases and methyllysine reader proteins.

Her research interests span Medicinal Chemistry, Epigenetics, Structure-Based Drug Design, PROTACs, Antiparasitic Agents, and Molecular Modeling. She has contributed significantly to the development of inhibitors for HDAC6, HDAC8 (including parasitic forms), LSD1, and Spindlin1, as well as NMDA receptor antagonists and bromodomain inhibitors.

The trend in her publications shows a deep engagement in designing small molecules for epigenetic targets, particularly in cancer and parasitic diseases. Her work combines computational methods like virtual screening and molecular dynamics with synthetic chemistry and biological evaluation. She frequently explores scaffold modifications, bioisosteric replacements, and structure-activity relationships to optimize drug candidates.

She has collaborated extensively with researchers such as W. Sippl, M. Jung, T. Wagner, and others across Germany and internationally, indicating active participation in research networks. While no formal advising or grant information is listed, her role as a co-author on numerous studies suggests mentorship and team leadership.

Her research group is involved in diverse projects including epigenetic drug discovery, antiparasitic agent development, and neuropharmacology, reflecting a multidisciplinary approach to medicinal chemistry.